Markets

Swedish cancer biotech Oasmia Pharmaceutical files for a $23 million US IPO

Oasmia Pharmaceutical, which is developing formulations of widely-used cancer drugs for humans and dogs, filed on Monday with the SEC to raise up to $23 million in a US initial public offering.

The company's shares are currently listed on the NASDAQ Stockholm under the symbol OASM and the Frankfurt Stock Exchange under the symbol OMAX. The development-stage pharmaceutical company commands a market cap of about $200 million.

The Uppsala, Sweden-based company, which was founded in 1999, plans to list on the NASDAQ under the symbol OASM. Oasmia Pharmaceutical initially filed confidentially on May 30, 2014. Ladenburg Thalmann is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Swedish cancer biotech Oasmia Pharmaceutical files for a $23 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More